Surgical Results from the NORTHSTAR Trial: Feasibility of Pulmonary Resection after Osimertinib in Stage IV disease
Presented During:
Saturday, May 6, 2023: 8:00AM - Tuesday, May 9, 2023: 11:45AM
Los Angeles Convention Center
Posted Room Name:
Outside of Room 408
Abstract No:
PS068
Submission Type:
Abstract Submission
Authors:
Mara Antonoff (1), Nathaniel Deboever (2), Mehmet Altan (3), Stephen Swisher (4), John Heymach (5), Boris Sepesi (6), Ara Vaporciyan (3), Saumil Gandhi (5), Yasir Elamin (3)
Institutions:
(1) MD Anderson Cancer Center, Bellaire, TX, (2) N/A, houston, TX, (3) UT MD Anderson Cancer Center, Houston, TX, (4) The University of Texas MD Anderson Cancer Center, Houston, TX, (5) University of Texas MD Anderson Cancer Center, Houston, TX, (6) The University of Texas M.D. Anderson Cancer Center, Houston, TX
Submitting Author:
*Mara Antonoff
-
Contact Me
MD Anderson Cancer Center
MD Anderson Cancer Center
Co-Author(s):
Nathaniel Deboever
-
Contact Me
N/A
N/A
Mehmet Altan
-
Contact Me
UT MD Anderson Cancer Center
UT MD Anderson Cancer Center
*Stephen Swisher
-
Contact Me
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
John Heymach
-
Contact Me
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Boris Sepesi
-
Contact Me
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center
*Ara Vaporciyan, MD
-
Contact Me
UT MD Anderson Cancer Center
UT MD Anderson Cancer Center
Saumil Gandhi
-
Contact Me
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Yasir Elamin
-
Contact Me
UT MD Anderson Cancer Center
UT MD Anderson Cancer Center
Presenting Author:
*Mara Antonoff
-
Contact Me
MD Anderson Cancer Center
MD Anderson Cancer Center
Abstract:
Background:
We have previously demonstrated that patients with oligometastatic non-small cell lung cancer (NSCLC) treated with local consolidative therapy (LCT) have improved survival outcomes compared to patients treated with systemic therapy alone, and that oligometastatic patients with EGFR mutations derive a more substantial benefit from LCT. A phase 2 randomized, multicenter study to evaluate the efficacy of osimertinib with or without LCT for patients with EGFR-mutant stage IV NSCLC (NORTHSTAR) was undertaken, including patients with oligo- as well as polymetastatic disease. We sought to assess feasibility and safety of lung resection in this patient population.
Methods:
Previously untreated patients with EGFR-mutant NSCLC (L858R, Ex19 deletion) or acquired EGFR T790M were enrolled in the NORTHSTAR trial. Patients with non-progressive disease after 6-12 weeks of osimertinib were randomized 1:1 to continue osimertinib alone or to undergo LCT + osimertinib. LCT patients underwent either surgery or radiation, and surgical patients were reviewed for details of intraoperative and 30-day postoperative courses. All procedures occurred between 06/2018-09/2022.
Results:
20 NORTHSTAR patients underwent lung resection, including 11 (55%) women, with median age of 65.1 years. 18 (90%) and 2 (10%) patients presented with poly- and oligometastatic disease, respectively. Procedures were performed by thoracotomy in 19 (95%) patients, and included 17 (85%) lobectomies, 1 (5%) wedge, and 2 (10%) segmentectomies. 3 (15%) had evidence of pretreatment malignant effusions. Surgeons reported operations as severely difficult in 17 (85%, Figure), with severe adhesions in 7 (35%) and severe hilar fibrosis in 13 (65%). Median operative duration and blood loss were 234 min (interquartile range [IQR] 154-271) and 175 mL (IQR 100-219), respectively, with 2 (10%) receiving intraoperative transfusion. There were no perioperative mortalities or ICU admissions. Median postoperative chest tube duration was 2.2 days (IQR: 1.4-2.7). Typical postoperative events occurred with prolonged airleak in 1 (5%) and atrial arrhythmias in 2 (10%).
Conclusions:
Patients with metastatic EGFR-mutated NSCLC who were randomized to LCT and underwent lung resection successfully achieved outcomes similar to historical standards for early-stage disease. These operations are feasible and safe, emphasizing the importance of including surgical resection in ongoing clinical trials for stage IV NSCLC.
We have previously demonstrated that patients with oligometastatic non-small cell lung cancer (NSCLC) treated with local consolidative therapy (LCT) have improved survival outcomes compared to patients treated with systemic therapy alone, and that oligometastatic patients with EGFR mutations derive a more substantial benefit from LCT. A phase 2 randomized, multicenter study to evaluate the efficacy of osimertinib with or without LCT for patients with EGFR-mutant stage IV NSCLC (NORTHSTAR) was undertaken, including patients with oligo- as well as polymetastatic disease. We sought to assess feasibility and safety of lung resection in this patient population.
Methods:
Previously untreated patients with EGFR-mutant NSCLC (L858R, Ex19 deletion) or acquired EGFR T790M were enrolled in the NORTHSTAR trial. Patients with non-progressive disease after 6-12 weeks of osimertinib were randomized 1:1 to continue osimertinib alone or to undergo LCT + osimertinib. LCT patients underwent either surgery or radiation, and surgical patients were reviewed for details of intraoperative and 30-day postoperative courses. All procedures occurred between 06/2018-09/2022.
Results:
20 NORTHSTAR patients underwent lung resection, including 11 (55%) women, with median age of 65.1 years. 18 (90%) and 2 (10%) patients presented with poly- and oligometastatic disease, respectively. Procedures were performed by thoracotomy in 19 (95%) patients, and included 17 (85%) lobectomies, 1 (5%) wedge, and 2 (10%) segmentectomies. 3 (15%) had evidence of pretreatment malignant effusions. Surgeons reported operations as severely difficult in 17 (85%, Figure), with severe adhesions in 7 (35%) and severe hilar fibrosis in 13 (65%). Median operative duration and blood loss were 234 min (interquartile range [IQR] 154-271) and 175 mL (IQR 100-219), respectively, with 2 (10%) receiving intraoperative transfusion. There were no perioperative mortalities or ICU admissions. Median postoperative chest tube duration was 2.2 days (IQR: 1.4-2.7). Typical postoperative events occurred with prolonged airleak in 1 (5%) and atrial arrhythmias in 2 (10%).
Conclusions:
Patients with metastatic EGFR-mutated NSCLC who were randomized to LCT and underwent lung resection successfully achieved outcomes similar to historical standards for early-stage disease. These operations are feasible and safe, emphasizing the importance of including surgical resection in ongoing clinical trials for stage IV NSCLC.
Categories:
Lung Cancer
Image or Table
